Blog
RSS FeedPosted by Michael Wonder on 13 Jan 2020
Novartis strikes deal with UK to provide cholesterol drug to high-risk patients
13 January 2020 - Pharmaceutical giant Novartis reached a deal with the U.K. to provide its late-stage cholesterol drug, inclisiran, to ...
Posted by Michael Wonder on 12 Jan 2020
The Tories must learn from the Orkambi victory and keep drug-pricing off the table
12 January 2020 - To match its rhetoric on the NHS, the government has to legally commit to preventing drug-pricing being ...
Posted by Michael Wonder on 07 Jan 2020
As Brexit nears, fears of an NHS sell-out resurface
6 January 2020 - In the lead up to December’s general election in Britain one of the main campaign issues ...
Posted by Michael Wonder on 04 Jan 2020
NICE refuses Akcea’s Waylivra
3 January 2020 - NICE has issued an Evaluation Consultation Document, refusing Waylivra (volanesorsen) as a treatment for familial chylomicronaemia ...
Posted by Michael Wonder on 03 Jan 2020
Additional evidence needed to assess histology-independent cancer drugs says paper co-authored by NICE staff
2 January 2020 - Paper looks at how histology-independent cancer drugs might be appraised. ...
Posted by Michael Wonder on 02 Jan 2020
Tecentriq hit with draft NICE rejection
2 December 2020 - NICE has issued a new draft guidance, advising against the use of Roche's Tecentriq (atezolizumab) for ...
Posted by Michael Wonder on 16 Dec 2019
NICE u-turn backs NHS use of Veltassa
16 December 2019 - The National Institute for Health and Care Excellence has given its stamp of approval for NHS ...
Posted by Michael Wonder on 12 Dec 2019
NICE and the SMC have published recommendations on Shionogi’s Mulpleo (lusutrombopag), approving its use for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
12 December 2019 - Mulpleo (lusutrombopag) is the first licensed treatment to be made available through the National Health Service ...
Posted by Michael Wonder on 10 Dec 2019
Biotech companies defend prices of one-off gene therapy
9 December 2019 - Latest treatments with price tags as high as $2 million require new financing models. ...
Posted by Michael Wonder on 07 Dec 2019
US pharma companies really do want Britain to pay more for drugs
6 December 2019 - When President Donald Trump arrived in the United Kingdom this week, he landed bang in the ...
Posted by Michael Wonder on 05 Dec 2019
Is it time to look beyond price with biosimilars?
5 December 2019 - While there is no question that falling prices that come with competition are cause for optimism in ...
Posted by Michael Wonder on 03 Dec 2019
The use of risk-sharing contracts in health care: theoretical and empirical assessments
3 December 2019 - The aim of this review is to provide a summary of the literature on risk-sharing agreements, including ...
Posted by Michael Wonder on 03 Dec 2019
Donald Trump says US would never take over any part of Britain’s NHS
3 December 2019 - US President Donald Trump has reassured the British public that even if the National Health Service ...
Posted by Michael Wonder on 02 Dec 2019
NICE grants Lynparza expansion for advanced ovarian cancer
2 December 2019 - Lynparza (olaparib), the joint MSD and AstraZeneca cancer drug, has been granted an expansion by NICE ...
Posted by Michael Wonder on 30 Nov 2019
Performance of UK National Health Service compared with other high income countries: observational study
27 November 2019 - The UK’s spending on health care has been constrained for some time, with slow growth in spending ...